ImmusanT’s celiac disease immunotherapy passes first clinical test – FierceBiotech
FierceBiotech |
ImmusanT's celiac disease immunotherapy passes first clinical test
FierceBiotech ImmusanT's big idea is to use a trio of three peptides as an immunotherapy that it hopes will encourage the T cells involved in the inflammatory reaction in celiac disease to become tolerant to gluten. After a first course to induce tolerance, the … ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 |
